← Back to Search

Probiotic

Kefir for Type 2 Diabetes

N/A
Waitlist Available
Led By Benjamin Willing, PhD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
With diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%)
Be older than 18 years old
Must not have
Gastrointestinal (GI) disorders of any kind
Monogenic dyslipidemias and endocrine disorders except for diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 weeks, 12 weeks

Summary

This trial aims to see if drinking traditional kefir can improve the heart health and immune system of people with Type 2 Diabetes over a period of 12 weeks.

Who is the study for?
This trial is for men and women at high risk of or living with Type 2 Diabetes who may also have cardiovascular issues. Participants should be interested in testing if kefir can improve their vascular health and immune system over a 12-week period.
What is being tested?
The study is examining the effects of traditional kefir compared to milk (which serves as a placebo) on vascular and immune health outcomes in individuals with or at high risk for Type 2 Diabetes.
What are the potential side effects?
Kefir may cause digestive discomfort, such as bloating, gas, or an upset stomach, especially in those who are lactose intolerant or not used to probiotic-rich foods.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Type 2 Diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a gastrointestinal disorder.
Select...
I have a genetic cholesterol disorder but not diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 weeks, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Glycated Hemoglobin (HbA1c) Levels (Percentage)
Secondary study objectives
Change in Circulating C-Reactive Protein (CRP) Levels (mg/L)
Change in Fasting Plasma Glucose Levels (mmol/L)
Change in Gut Microbiome Composition and Functional Capacity (Relative Abundance)
+7 more
Other study objectives
Change in Body Composition (Percentage of Fat Mass and Fat-Free Mass) Measured by Bioelectrical Impedance Analysis (BIA)
Change in Body Mass Index (BMI) (kg/m²)
Change in Hip Circumference (cm)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Participants with higher risk of T2DExperimental Treatment2 Interventions
Randomly assigned to consume either traditional kefir or milk as a placebo.
Group II: Participants living with T2DExperimental Treatment2 Interventions
Randomly assigned to consume either traditional kefir or milk as a placebo.

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
941 Previous Clinical Trials
433,965 Total Patients Enrolled
8 Trials studying Diabetes
42,167 Patients Enrolled for Diabetes
Benjamin Willing, PhDPrincipal InvestigatorUniversity of Alberta
~87 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top